Pulmonx (LUNG) Competitors $3.14 -0.21 (-6.27%) As of 02:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LUNG vs. BFLY, KIDS, RXST, BVS, AXGN, DCTH, TMCI, NPCE, CLPT, and SMLRShould you be buying Pulmonx stock or one of its competitors? The main competitors of Pulmonx include Butterfly Network (BFLY), OrthoPediatrics (KIDS), RxSight (RXST), Bioventus (BVS), AxoGen (AXGN), Delcath Systems (DCTH), Treace Medical Concepts (TMCI), NeuroPace (NPCE), ClearPoint Neuro (CLPT), and Semler Scientific (SMLR). These companies are all part of the "medical equipment" industry. Pulmonx vs. Butterfly Network OrthoPediatrics RxSight Bioventus AxoGen Delcath Systems Treace Medical Concepts NeuroPace ClearPoint Neuro Semler Scientific Pulmonx (NASDAQ:LUNG) and Butterfly Network (NYSE:BFLY) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, community ranking, analyst recommendations, risk and institutional ownership. Which has stronger valuation and earnings, LUNG or BFLY? Pulmonx has higher revenue and earnings than Butterfly Network. Butterfly Network is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPulmonx$87.47M1.45-$60.84M-$1.44-2.18Butterfly Network$85.63M6.31-$133.70M-$0.29-7.53 Do insiders and institutionals have more ownership in LUNG or BFLY? 91.0% of Pulmonx shares are held by institutional investors. Comparatively, 37.8% of Butterfly Network shares are held by institutional investors. 6.8% of Pulmonx shares are held by company insiders. Comparatively, 25.2% of Butterfly Network shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community believe in LUNG or BFLY? Pulmonx received 31 more outperform votes than Butterfly Network when rated by MarketBeat users. However, 72.73% of users gave Butterfly Network an outperform vote while only 47.56% of users gave Pulmonx an outperform vote. CompanyUnderperformOutperformPulmonxOutperform Votes3947.56% Underperform Votes4352.44% Butterfly NetworkOutperform Votes872.73% Underperform Votes327.27% Is LUNG or BFLY more profitable? Pulmonx has a net margin of -67.31% compared to Butterfly Network's net margin of -129.25%. Butterfly Network's return on equity of -42.68% beat Pulmonx's return on equity.Company Net Margins Return on Equity Return on Assets Pulmonx-67.31% -55.36% -33.53% Butterfly Network -129.25%-42.68%-30.31% Does the media refer more to LUNG or BFLY? In the previous week, Pulmonx had 3 more articles in the media than Butterfly Network. MarketBeat recorded 4 mentions for Pulmonx and 1 mentions for Butterfly Network. Butterfly Network's average media sentiment score of 1.67 beat Pulmonx's score of 1.15 indicating that Butterfly Network is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulmonx 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Butterfly Network 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has more risk & volatility, LUNG or BFLY? Pulmonx has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, Butterfly Network has a beta of 2.59, meaning that its share price is 159% more volatile than the S&P 500. Do analysts recommend LUNG or BFLY? Pulmonx currently has a consensus target price of $12.07, indicating a potential upside of 284.44%. Butterfly Network has a consensus target price of $4.00, indicating a potential upside of 83.07%. Given Pulmonx's higher probable upside, equities research analysts clearly believe Pulmonx is more favorable than Butterfly Network.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pulmonx 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78Butterfly Network 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryPulmonx and Butterfly Network tied by winning 9 of the 18 factors compared between the two stocks. Get Pulmonx News Delivered to You Automatically Sign up to receive the latest news and ratings for LUNG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LUNG vs. The Competition Export to ExcelMetricPulmonxSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$126.61M$4.50B$5.38B$8.42BDividend YieldN/A43.64%5.22%4.11%P/E Ratio-2.1829.5826.6219.77Price / Sales1.4568.44392.02116.56Price / CashN/A51.0838.2534.62Price / Book1.026.256.814.53Net Income-$60.84M$68.16M$3.23B$248.18M7 Day Performance-3.68%18.41%4.05%1.06%1 Month Performance-30.53%23.13%11.64%14.68%1 Year Performance-64.24%20.79%17.11%6.87% Pulmonx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LUNGPulmonx3.5245 of 5 stars$3.14-6.3%$12.07+284.4%-62.4%$126.61M$87.47M-2.18250Positive NewsBFLYButterfly Network2.7815 of 5 stars$2.35+5.2%$4.00+70.6%+122.3%$579.89M$85.63M-5.10460Positive NewsKIDSOrthoPediatrics4.6164 of 5 stars$23.27+5.6%$35.83+54.0%-29.6%$565.16M$204.73M-18.92200Positive NewsRXSTRxSight3.0678 of 5 stars$13.75+5.3%$37.60+173.5%-73.5%$558.76M$148.31M-16.57220Positive NewsAnalyst UpgradeHigh Trading VolumeBVSBioventus3.2922 of 5 stars$6.74+0.9%$14.33+112.7%+12.2%$552.30M$567.70M-11.051,200Positive NewsAXGNAxoGen3.4241 of 5 stars$11.39+0.3%$22.60+98.4%+86.6%$518.64M$187.34M-35.59450DCTHDelcath Systems3.1205 of 5 stars$14.45-2.6%$22.75+57.4%+123.8%$483.11M$37.21M-10.7060News CoverageGap UpTMCITreace Medical Concepts2.3204 of 5 stars$7.20+5.6%$10.16+41.1%+35.4%$452.81M$210.82M-7.27250Trending NewsNPCENeuroPace1.4895 of 5 stars$13.37+3.7%$15.20+13.7%+125.4%$437.91M$79.91M-13.37170CLPTClearPoint Neuro1.7418 of 5 stars$13.64-3.3%$25.00+83.3%+108.6%$381.65M$31.39M-19.77110Gap DownSMLRSemler Scientific2.5738 of 5 stars$34.84+0.1%$71.00+103.8%+78.4%$334.36M$56.29M7.10120Options VolumeGap UpHigh Trading Volume Related Companies and Tools Related Companies Butterfly Network Competitors OrthoPediatrics Competitors RxSight Competitors Bioventus Competitors AxoGen Competitors Delcath Systems Competitors Treace Medical Concepts Competitors NeuroPace Competitors ClearPoint Neuro Competitors Semler Scientific Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LUNG) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulmonx Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pulmonx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.